ATE292465T1 - Benzimidazol-derivate als ige-modulatoren - Google Patents

Benzimidazol-derivate als ige-modulatoren

Info

Publication number
ATE292465T1
ATE292465T1 AT99924442T AT99924442T ATE292465T1 AT E292465 T1 ATE292465 T1 AT E292465T1 AT 99924442 T AT99924442 T AT 99924442T AT 99924442 T AT99924442 T AT 99924442T AT E292465 T1 ATE292465 T1 AT E292465T1
Authority
AT
Austria
Prior art keywords
ige
benzimidazole derivatives
modulators
ige modulators
allergens
Prior art date
Application number
AT99924442T
Other languages
English (en)
Inventor
Jagadish Sircar
Mark L Richards
Michael G Campbell
Michael W Major
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE292465(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Application granted granted Critical
Publication of ATE292465T1 publication Critical patent/ATE292465T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
AT99924442T 1998-05-22 1999-05-21 Benzimidazol-derivate als ige-modulatoren ATE292465T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011322 WO1999061019A1 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE

Publications (1)

Publication Number Publication Date
ATE292465T1 true ATE292465T1 (de) 2005-04-15

Family

ID=22198947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99924442T ATE292465T1 (de) 1998-05-22 1999-05-21 Benzimidazol-derivate als ige-modulatoren

Country Status (22)

Country Link
US (2) US6271390B1 (de)
EP (3) EP1077700B1 (de)
JP (3) JP2002516274A (de)
KR (1) KR100591652B1 (de)
CN (4) CN1311675A (de)
AT (1) ATE292465T1 (de)
AU (3) AU4197899A (de)
BR (3) BR9910641A (de)
CA (3) CA2332985A1 (de)
CZ (2) CZ20004351A3 (de)
DE (1) DE69924607T2 (de)
ES (1) ES2241285T3 (de)
HU (3) HUP0101894A3 (de)
IL (3) IL139828A0 (de)
MX (3) MXPA00011470A (de)
NO (3) NO20005889L (de)
NZ (2) NZ508416A (de)
PL (3) PL345952A1 (de)
RU (2) RU2236220C2 (de)
UA (2) UA67774C2 (de)
WO (3) WO1999061013A2 (de)
ZA (3) ZA200007754B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
WO1999061013A2 (en) * 1998-05-22 1999-12-02 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
EP1113000A4 (de) 1998-09-11 2004-12-15 Ajinomoto Kk Benzolderivate und ihre medizinische anwendung
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
ES2345921T3 (es) * 1999-03-26 2010-10-06 Euro-Celtique S.A. Pirazoles, imidazoles, oxazoles, tiazoles y pirroles sustituidos con arilo y su uso.
MXPA02000253A (es) * 1999-07-01 2002-06-21 Ajinomoto Kk Compuestos heterociclicos y uso medico de los mismos.
EP1211240A4 (de) 1999-09-01 2003-02-12 Ajinomoto Kk Biscyclopropanecarbonsäureamid-verbindungen und deren medizinische verwendung
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
ES2291455T3 (es) * 2001-03-12 2008-03-01 Avanir Pharmaceuticals Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
EP2335700A1 (de) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C Virus Polymerase Inhibitoren mit heterobicylischer Struktur
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE60221866T2 (de) 2001-10-19 2008-05-29 Ortho-Mcneil Pharmaceutical, Inc. 2-PHENYL BENZIMIDAZOLE UND IMIDAZO-i4,5ö-PYRIDINE ALS CDS1/CHK2-INHIBITOREN UND ADJUVANTIEN IN DER CHEMOTHERAPIE ODER STRAHLUNGSTHERAPIE ZUR BEHANDLUNG VON KREBS
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
EP1388535A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte Arylcycloalkylamine und ihre Anwendung als Arzneimittelwirkstoff
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
AU2003277689A1 (en) * 2002-11-02 2004-06-07 Kyung-Lim Lee Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
AU2004263190A1 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
UY28758A1 (es) 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
ATE453617T1 (de) * 2004-05-12 2010-01-15 Proteotech Inc Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
DE602005027739D1 (de) 2004-06-30 2011-06-09 Janssen Pharmaceutica Nv Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
WO2007070173A2 (en) † 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
EP1790345A1 (de) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-Secretase-Inhibitoren
AU2006336504C9 (en) * 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
WO2010075380A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
EP2419404B1 (de) 2009-04-15 2015-11-04 AbbVie Inc. Anti virale verbindungen
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EP2509975B1 (de) * 2009-12-04 2014-04-23 Boehringer Ingelheim International GmbH Benzimidazolhemmer der leukotrienproduktion
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CN103052628B (zh) * 2010-07-20 2016-05-18 韦斯塔隆公司 三嗪类和嘧啶类杀虫剂
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
JP5789888B2 (ja) 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN115215838B (zh) * 2018-09-18 2025-04-04 拓臻股份有限公司 用于治疗特定白血病的化合物
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
EP0469477B1 (de) * 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergische Mischung
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
ATE150447T1 (de) * 1992-06-15 1997-04-15 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
RU2084451C1 (ru) * 1995-10-17 1997-07-20 Акционерное общество закрытого типа "Алмазный Центр" Способ получения 2-фенилбензимидазола
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
WO1999061013A2 (en) * 1998-05-22 1999-12-02 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
EP1342199A1 (de) * 2000-11-15 2003-09-10 Manugistics Atlanta, Inc. Angebotspreisbildungssystem und -verfahren
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
EP1077700B1 (de) 2005-04-06
IL139828A0 (en) 2002-02-10
ES2241285T3 (es) 2005-10-16
IL139826A0 (en) 2002-02-10
DE69924607T2 (de) 2006-02-02
NO20005888D0 (no) 2000-11-21
ZA200007753B (en) 2001-07-18
NZ508416A (en) 2004-01-30
JP2002516276A (ja) 2002-06-04
PL345952A1 (en) 2002-01-14
RU2236221C2 (ru) 2004-09-20
US6451829B2 (en) 2002-09-17
RU2236220C2 (ru) 2004-09-20
DE69924607D1 (de) 2005-05-12
WO1999061019A1 (en) 1999-12-02
NO20005888L (no) 2001-01-22
AU4312099A (en) 1999-12-13
BR9910640A (pt) 2001-10-30
ZA200007752B (en) 2001-12-05
HUP0101894A3 (en) 2002-07-29
CZ20004350A3 (cs) 2002-02-13
WO1999061013A3 (en) 2000-04-06
CN1311679A (zh) 2001-09-05
US20020010343A1 (en) 2002-01-24
NO20005889D0 (no) 2000-11-21
EP1077700A1 (de) 2001-02-28
CA2332985A1 (en) 1999-12-02
HUP0102128A2 (hu) 2002-03-28
NZ508413A (en) 2003-08-29
HUP0102128A3 (en) 2002-05-28
PL345219A1 (en) 2001-12-03
AU754562B2 (en) 2002-11-21
CN1311675A (zh) 2001-09-05
CN1219510C (zh) 2005-09-21
BR9910642A (pt) 2001-10-09
HUP0101894A2 (hu) 2002-02-28
ZA200007754B (en) 2001-08-16
EP1077695A2 (de) 2001-02-28
AU4197899A (en) 1999-12-13
MXPA00011467A (es) 2002-10-17
KR100591652B1 (ko) 2006-06-26
KR20010030179A (ko) 2001-04-16
BR9910641A (pt) 2001-10-02
NO20005889L (no) 2001-01-22
EP1079830A1 (de) 2001-03-07
WO1999061020A1 (en) 1999-12-02
HUP0102550A3 (en) 2002-11-28
UA67775C2 (uk) 2004-07-15
MXPA00011470A (es) 2002-10-17
WO1999061013A2 (en) 1999-12-02
NO20005887L (no) 2001-01-19
JP2002516277A (ja) 2002-06-04
CA2332989A1 (en) 1999-12-02
AU754943B2 (en) 2002-11-28
NO20005887D0 (no) 2000-11-21
UA67774C2 (uk) 2004-07-15
IL139827A0 (en) 2002-02-10
US6271390B1 (en) 2001-08-07
MXPA00011422A (es) 2002-12-13
HUP0102550A2 (hu) 2001-10-28
PL345560A1 (en) 2001-12-17
CZ20004351A3 (cs) 2001-10-17
JP2002516274A (ja) 2002-06-04
CN1721411A (zh) 2006-01-18
CN1317965A (zh) 2001-10-17
CA2332999A1 (en) 1999-12-02
AU4094299A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
DE69924607D1 (de) Benzimidazol-derivate als ige-modulatoren
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
NO20025376L (no) Nye multicykliske forbindelser og anvendelser derav
DE69811363D1 (de) Piperazin-derivate und ihre verwendung als entzündungshemmende mittel
BR0314223A (pt) Compostos fenil-indol para modular ige e inibir proliferação celular
BRPI0409097A (pt) derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE401906T1 (de) Sedative stoffe und behandlungen
ATE305041T1 (de) Kompositionen und verwendungen von cgi-69
EP1317271A4 (de) Therapeutische und kosmetische verwendungen von hepanasen
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
DE60018192D1 (de) Behandlung von konjunktivitis mit histacalin proteinen
DE50200757D1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
SE9901273D0 (sv) Novel compounds
DE50214750D1 (de) Kinase inhibitoren und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties